Abstract: A pyridopyrimidinone derivative as represented by formula I, and a tautomer, a stereoisomer, a hydrate, a solvate, a pharmaceutically acceptable salt thereof or a prodrug thereof. The pyridopyrimidinone derivative has a good SOS1 inhibitory effect.
Type:
Application
Filed:
February 8, 2022
Publication date:
May 23, 2024
Applicant:
Wuhan Humanwell Innovative Drug Research and Development Center Limited Company
Inventors:
Xuejun ZHANG, Shaohua CHANG, Xueqiang LI, Dabing YE, Hongqiang WANG, Hongna SUN, Jun YANG, Li'e LI
Abstract: The present disclosure provides a novel compound for effectively inhibiting the activity of CD73, a preparation method thereof, and use thereof in the preparation of drugs, and the novel compound is a compound represented by formula I, or a tautomer, stereoisomer, hydrate, solvate, pharmaceutically acceptable salt, or prodrug thereof.
Type:
Application
Filed:
November 5, 2021
Publication date:
December 14, 2023
Applicant:
WUHAN HUMANWELL INNOVATIVE DRUG RESEARCH AND DEVELOPMENT CENTER LIMITED COMPANY
Inventors:
Xuejun ZHANG, Shaohua CHANG, Dabing YE, Sijun LEI, Yonggang WANG, Yong LIU, Hongna SUN, Jun YANG, Lie LI
Abstract: Provided are salts of a compound of formula (I) having an ATX inhibitory activity. The salts comprises inorganic acid salts or organic acid salts, and solid forms of the salts, such as crystal forms. The salts of the compound of formula (I) and their crystal forms according to the present disclosure have a good solubility, stability and hygroscopicity, and are more suitable for medicinal use. Moreover, their preparation methods are simple and convenient, and are suitable for large-scale production.
Type:
Application
Filed:
July 28, 2021
Publication date:
October 5, 2023
Applicant:
Wuhan Humanwell Innovative Drug Research And Development Center Limited Company
Inventors:
Xuejun Zhang, Yang Yue, Sijun Lei, Qingfeng Xia, Yuan Li, Qiongfeng Yang, Min'an Liu, Shaoxia Yang, Ming Liu, Bin Hu, Shoubo Zhang, Xiaohua Ding, Zhe Liu
Abstract: Provided are a novel compound that effectively antagonizes P2X3 receptor, a preparation method thereof, and use thereof in the preparation of drugs. The compound is a compound represented by Formula I, or a tautomer, a stereoisomer, a hydrate, a solvate, a pharmaceutically acceptable salt, or a prodrug thereof.
Type:
Application
Filed:
March 28, 2023
Publication date:
July 20, 2023
Applicants:
HUMANWELL HEALTHCARE (GROUP) CO., LTD., WUHAN HUMANWELL INNOVATIVE DRUG RESEARCH AND DEVELOPMENT CENTER LIMITED COMPANY
Inventors:
Xuejun ZHANG, Yang ZANG, Xueqiang LI, Chengbing YANG, Yonggang WANG, Bo ZHANG, Yang LI, Lifei LIU, Jun YANG, Lie LI
Abstract: The present disclosure provides a novel compound effective in antagonizing EP4, which is a compound represented by Formula I, or a tautomer, stereoisomer, hydrate, solvate, pharmaceutically acceptable salt or prodrug of the compound represented by Formula I: wherein: R1 is selected from —CH3, —CHF2, and —CF3; R2 is selected from C2-C6 alkyl, C3-C6 cycloalkyl, C2-C6 halogen-substituted alkyl, C3-C6 halogen-substituted cycloalkyl; R3 is selected from hydrogen, halogen, C1-C2 alkyl, C1-C2 fluorine- or chlorine-substituted alkyl; R4 is selected from hydrogen, halogen, C1-C6 alkyl, C1-C6 alkoxyl, C1-C6 halogen-substituted alkyl, C1-C6 halogen-substituted alkoxyl.
Type:
Application
Filed:
March 4, 2021
Publication date:
April 27, 2023
Applicant:
Wuhan Humanwell Innovative Drug Research And Development Center Limited Company
Inventors:
Xuejun ZHANG, Yang ZANG, Lie LI, Jie SHEN, Zhe LIU, Shaohua CHANG, Yonggang WANG
Abstract: The present disclosure relates to pyrimidine compounds, and more specifically, relates to pyrimidine compounds, preparation methods thereof, and uses thereof in manufacture of medicaments. Provided is a compound represented by Formula (I) or a tautomer, stereoisomer, hydrate, solvate, pharmaceutical acceptable salt, or prodrug of the compound represented by Formula (I). The compound has a significant inhibitory effect on ATX enzyme, exhibits excellent liver metabolism stability, is metabolized more slowly in the human body, and has higher exposure.
Type:
Application
Filed:
March 4, 2022
Publication date:
June 30, 2022
Applicant:
Wuhan Humanwell Innovative Drug Research And Development Center Limited Company
Inventors:
Xuejun ZHANG, Lie LI, Jie SHEN, Wenjun WEI, Sijun LEI, Xiaohua DING, Yang ZANG, Hongna SUN, Qiangqiang FU